期刊
MOVEMENT DISORDERS
卷 25, 期 12, 页码 1774-1779出版社
WILEY
DOI: 10.1002/mds.23288
关键词
Parkinson's disease; Disease modification; Clinical trials; Delayed start study; Long term simple study
资金
- NIH
- MJ Fox Foundation
- Medivation
- Neurosearch
- BI
A disease-modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long-term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. (C) 2010 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据